Provided by Tiger Trade Technology Pte. Ltd.

Post-Pandemic Stocks

916.699
-8.566-0.93%
Number of Gainers:6
Number of Losers:9
Number of Flat:2
PE:- -
High:925.384
Open:925.265
Low:913.375
Close:925.265
Volume:260.39M
Turnover:2.37B
Market Cap:616.77B
Float Cap:513.79B

Loading ...

Weak Dollar and Shifting Tech Narratives: Strategists Favor Resources and Pharma

Stock News
·
Aug 23

Alibaba's Record HK$80 Billion Share Placement: A 3.6%-9% Discount Strategy Unveiled

Deep News
·
Aug 23

BofA Securities Lifts CSPC Pharma Target Price to HK$8.6 While Maintaining Underperform Rating

Deep News
·
Aug 23

UBS Lifts CSPC Pharma Price Target to HK$11.80, Reiterates Buy Rating

Deep News
·
Aug 23

Goldman Sachs Adjusts CSPC Pharma Target Price Upward While Retaining Buy Stance

Deep News
·
Aug 23

CSPC Pharmaceutical Group Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Simply Wall St.
·
Aug 23

Ping An Healthcare And Technology (SEHK:1833) Reported Profits, Is The Stock Fully Priced?

Simply Wall St.
·
Aug 22

Sino Biopharmaceutical (SEHK:1177) Could Be 66% Below Fair Value As Earnings Lift Interest

Simply Wall St.
·
Aug 22

Niki BioSolutions Weighs Financing Options as Going-Concern Warning Clouds Post-Merger Outlook

Reuters
·
Aug 22

Ascletis Pharma Expects HY Loss of Rmb319.7 MLN

Reuters
·
Aug 21

BAIYUNSHAN PH Reports Interim Results with Net Profit Attributable to Shareholders of Approximately RMB 2.096 Billion, Down 16.7% Year-on-Year

Stock News
·
Aug 21

China's Haohai Biological H1 Revenue Falls, Partly Hurt by End of Brighten Optix Distribution

Reuters
·
Aug 21

Ascletis Pharma-B Warns of 263.5% Surge in Interim Loss to Roughly RMB 319.7 Million

Stock News
·
Aug 21

Ascletis Pharma Sees H1 Loss Widening to RMB 319.7 Million

Reuters
·
Aug 21

Ascletis Pharma - Expects Loss of Rmb319.7 Mln for H1 2026, up 263.5% YoY

THOMSON REUTERS
·
Aug 21

Ascletis Pharma - Expected Hy Result as R&D Expenses Increased 132.7% to Rmb341.7 Mln, Others

THOMSON REUTERS
·
Aug 21

Junshi Biosciences Raises 700 Million Yuan Through Tech Innovation Bond Issuance

Stock News
·
Aug 21

SBP Group's Novel Weight Management Therapy Gains Regulatory Nod for Clinical Trials

Stock News
·
Aug 21

Henan Chemical Firm Commits 38 Million Yuan to Revamp Pharmaceutical Intermediate Facility

Deep News
·
Aug 21

UOB Kay Hian Upgrades CSPC Pharmaceutical Group to Buy from Sell; Price Target is HK$11.50

MT Newswires Live
·
Aug 21